FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer By Ogkologos - February 6, 2025 651 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the eXALT3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR EMA Recommends Extending Indications for Zanubrutinib to Include Treatment of Patients... November 2, 2023 Expanding the horizons of the life science economy May 3, 2022 Tobacco-Related Deaths Claim Almost 60,000 Women’s Lives Each Year, And Are... February 18, 2021 FDA Grants Accelerated Approval to Umbralisib for Marginal Zone and Follicular... February 11, 2021 Load more HOT NEWS The Late Alex Trebek’s Wardrobe Is Being Given to Homeless Men... Fear Perioperative Chemotherapy with FLOT Improves Survival Among Patients with Resectable Oesophageal... NCI Expands Repository of Cancer Research Models: A Conversation with Drs....
